{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:30:57Z","timestamp":1790353857240,"version":"4.1.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:p>We report the case of a 61-year-old patient with relapsing\u2013remitting multiple sclerosis (RRMS) who developed asymptomatic macular edema (ME) after initiation of ozanimod, a sphingosine-1-phosphate receptor (S1PR) modulator. The patient had a history of completely resolved central serous choroidopathy (CSC) in the right eye. Following a recent clinical worsening and a new brain lesion, ozanimod was started after appropriate screening, including ophthalmological evaluation. Three months into treatment, an OCT performed as part of routine monitoring revealed ME in the contralateral (left) eye, despite the absence of visual symptoms. Ozanimod was discontinued, and ME progressively resolved over the subsequent 2 months. This case underscores the importance of ophthalmological monitoring even in asymptomatic patients, especially those with known risk factors such as prior retinal pathology. ME is a rare but recognized adverse event associated with all approved <jats:italic>-imod<\/jats:italic> therapies for MS, including ozanimod. Although the exact pathophysiology remains unclear, involvement of the inner blood\u2013retina barrier via S1PR1 internalization has been hypothesized. Given ozanimod\u2019s long half-life and active metabolites, ME resolution may be delayed after drug withdrawal. This report highlights the relevance of interdisciplinary management and the utility of OCT in early detection of asymptomatic ocular adverse events during S1PR modulator therapy.<\/jats:p>","DOI":"10.3389\/fopht.2025.1632065","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:25:16Z","timestamp":1759850716000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Asymptomatic macular edema in ozanimod"],"prefix":"10.3389","volume":"5","author":[{"given":"Valentina Annamaria","family":"Mauceri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Torresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Basili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gaggiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Puthenparampil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): A randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518789884","article-title":"Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study","volume":"25","author":"Cohen","year":"2019","journal-title":"Multiple Sclerosis J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221102584","article-title":"Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial","volume":"28","author":"Cree","year":"2022","journal-title":"Multiple Sclerosis J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820d5ec1","article-title":"Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation","volume":"76","author":"Hla","year":"2011","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52017","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review","volume":"11","author":"Coyle","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0052-x","article-title":"Anti-CD69 therapy induces rapid mobilization and high proliferation of HSPCs through S1P and mTOR","volume":"32","author":"Notario","year":"2018","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-025-00725-6","article-title":"Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data","volume":"77","author":"Balzano","year":"2025","journal-title":"Pharmacol Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051290","article-title":"Central modulation of selective sphingosine-1-phosphate receptor 1 ameliorates experimental multiple sclerosis","volume":"9","author":"Musella","year":"2020","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms161226177","article-title":"Fingolimod (FTY720-P) does not stabilize the blood\u2013brain barrier under inflammatory conditions in an in Vitro model","volume":"16","author":"Schuhmann","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102844","DOI":"10.1016\/j.msard.2021.102844","article-title":"Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program","volume":"51","author":"Selmaj","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B15","doi-asserted-by":"publisher","first-page":"H33","DOI":"10.1152\/ajpheart.00097.2008","article-title":"Balance of S1P1 and S1P2 signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature","volume":"296","author":"Lee","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12883-023-03333-0","article-title":"Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review","volume":"23","author":"Li","year":"2023","journal-title":"BMC Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/24741264231215537","article-title":"Ponesimod-associated macular edema: onset and resolution","volume":"8","author":"Singh","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41520","article-title":"Fingolimod-associated macular edema in the treatment of multiple sclerosis","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1632065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:25:17Z","timestamp":1759850717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1632065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":18,"alternative-id":["10.3389\/fopht.2025.1632065"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2025.1632065","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"article-number":"1632065"}}